Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma

Wang, Zong Ren; Wei, Jin; Zhou, Jianyin; Haddad, Ahmed; Zhao, Liang; Kapur, Payal; Wu, Kai; Wang, Bin; Yu, Yinhua; Liao, Bing; He, Da Lin; Chen, Wei; Margulis, Vitaly; Hsieh, Jer Tsong; Luo, Jun

doi:10.18632/oncotarget.8971

Cited by 24 publications

(23 citation statements)

References 34 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each year, approximate 270,000 cases will be diagnosed as having renal cancer around the world 16-18. At present, considering the use of advanced instruments and innovative therapy, some cases of ccRCC can be diagnosed at early stages and cured by surgical resection and chemo-radiotherapy 5.…”

Section: Discussionmentioning

confidence: 99%

Overexpression of G6PD Represents a Potential Prognostic Factor in Clear Cell Renal Cell Carcinoma

Zhang¹,

Yi²,

Yang³

et al. 2017

J. Cancer

View full text Add to dashboard Cite

Glucose-6-phosphate dehydrogenase (G6PD) participates in glucose metabolism and it acts as the rate-limiting enzyme of the pentose phosphate pathway (PPP). Recently, G6PD dysregulation has been found in a variety of human cancers. Through analyzing published data in The Cancer Genome Atlas (TCGA), our pilot study indicated that G6PD mRNA expression was significantly higher in advanced Fuhrman grade in clear cell renal cell carcinoma (ccRCC). These clues promoted us to further evaluate the expression profile of G6PD and its prognostic impact in patients with ccRCC. In this study, G6PD expression levels were analyzed in 149 human ccRCC and normal tissues using immunohistochemistry. The results showed that compared with that in the normal renal samples, G6PD was found highly expressed in 51.0% of ccRCC (p<0.05). High expression of G6PD was significantly correlated to tumor extent, lymph node metastasis, Fuhrman grade, and TNM stage of ccRCC (all p<0.05). Moreover, positive G6PD expression was associated with poorer overall survival in ccRCC (p<0.001). In Cox regression analyses, high expression of G6PD also could be an independent prognostic factor for overall survival in ccRCC (p=0.007). This study suggests that overexpression of G6PD is associated with advanced disease status and therefore may become an important prognosticator for poor outcomes in ccRCC, as well as a potential therapeutic target for developing effective treatment modalities.

show abstract

Section: Discussionmentioning

confidence: 99%

Overexpression of G6PD Represents a Potential Prognostic Factor in Clear Cell Renal Cell Carcinoma

Zhang¹,

Yi²,

Yang³

et al. 2017

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Such a rich collection of data gathered from a large number of patients have a great potential to be used in robust statistical analyses, thereby enabling improved survival prediction. Therefore, several studies [35,36,43,[47][48][49][50] rely on TCGA as a complementary resource for biomarker assessment. We believe that MethSurv will be a promising tool for similar studies to explore methylation-based biomarkers and to perform in silico validation as illustrated in the case studies section.…”

mentioning

confidence: 99%

MethSurv: A Web Tool to Perform Multivariable Survival Analysis Using DNA Methylation Data

et al. 2017

View full text Add to dashboard Cite

Aim:To develop a web tool for survival analysis based on CpG methylation patterns. Materials & methods: We utilized methylome data from 'The Cancer Genome Atlas' and used the Cox proportional-hazards model to develop an interactive web interface for survival analysis. Results: MethSurv enables survival analysis for a CpG located in or around the proximity of a query gene. For further mining, cluster analysis for a query gene to associate methylation patterns with clinical characteristics and browsing of top biomarkers for each cancer type are provided. MethSurv includes 7358 methylomes from 25 different human cancers. Conclusion: The MethSurv tool is a valuable platform for the researchers without programming skills to perform the initial assessment of methylation-based cancer biomarkers.

show abstract

“…In addition, we performed Kaplan-Meier analysis to evaluate the association of methylated CLDN11 with overall survival. We used the mean methylation level of tumor tissues to classify patients into two groups: 30 patients were placed into the hypermethylation group, and the remaining patients were categorized as the hypomethylation group [ 29 ]. Kaplan-Meier analysis indicated that patients with higher methylation frequency tended to have a poorer overall survival compared to patients with lower methylation (log-rank test, p =0.007, Figure 3 ).…”

Section: Resultsmentioning

confidence: 99%

The Clinical Signification of Claudin-11 Promoter Hypermethylation for Laryngeal Squamous Cell Carcinoma

et al. 2017

View full text Add to dashboard Cite

BackgroundClaudin-11 (CLDN11) is frequently silenced by its promoter hypermethylation. Previous studies have shown that CLDN11 promoter hypermethylation is a potential biomarker for diagnosing various cancers. The aim of this study was to investigate CLDN11 promoter methylation and its potential relevance to clinicopathologic features and prognosis of patients with laryngeal squamous cell carcinoma (LSCC).Material/MethodsUsing the quantitative methylation-specific polymerase chain reaction (qMSP), CLDN11 promoter methylation was measured in 91 tumor tissues and their paired adjacent normal tissues, and the relationship between CLDN11 methylation and clinicopathologic features was evaluated. A receiver operating characteristic (ROC) curve was created to assess diagnostic values, and the Kaplan-Meier survival analysis was used to evaluate the association between CLDN11 methylation and prognosis of patients with LSCC.ResultsOur results showed significantly elevated promoter methylation of CLDN11 in tumor tissues compared to their adjacent tissues (p=1.227E-16). CLDN11 promoter methylation also increased in patients with lymph node metastasis (p=0.009), advanced clinical stage (p=9.26E-06) and higher T classification (p=0.003). The area under the ROC curve (AUC) of CLDN11 was 0.884 (95% CI=0.835–0.932, p<0.01). The Kaplan-Meier analysis indicated that high CLDN11 promoter methylation levels were associated with poor overall survival of LSCC patients (log-rank test, p=0.007).ConclusionsWe demonstrated that CLDN11 promoter hypermethylation is a frequent event in LSCC, and contributes to metastasis and progression of LSCC. Thus, CLDN11 could be a potential biomarker for diagnosis and prognosis of LSCC patients.

show abstract

Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma

Cited by 24 publications

References 34 publications

Overexpression of G6PD Represents a Potential Prognostic Factor in Clear Cell Renal Cell Carcinoma

Overexpression of G6PD Represents a Potential Prognostic Factor in Clear Cell Renal Cell Carcinoma

MethSurv: A Web Tool to Perform Multivariable Survival Analysis Using DNA Methylation Data

The Clinical Signification of Claudin-11 Promoter Hypermethylation for Laryngeal Squamous Cell Carcinoma

Contact Info

Product

Resources

About